Weekly drug-trial and regulatory update recap for AstraZeneca

A weekly recap of AstraZeneca pipeline developments highlights Enhertu efficacy in HER2-mutant NSCLC (PFS/ORR gains), CHMP and NHS progress for HER2 breast cancer adjuvant therapy, and ongoing uncertainties around safety/OS plus late-stage failures and mixed analyst views affecting expectations for the stock and pipeline.